Insights On Enterprise Solutions

  1. Leveraging Efficiency From CLD To Clinical Manufacturing Of mAbs 2/4/2026

    Discover how our efficient strategies can propel your mAb from discovery to clinical manufacturing in as little as 18 months.

  2. Leveraging The Immunological Diversity Of The Pentamice® Platform For Covid-19 Antibody Discovery 2/4/2026

    Consider this alternative immunization approach — the PentaMice platform, a collection of five wildtype mouse strains bred in-house for increased MHC class II diversity — and how we're leveraging it for COVID-19 antibody discovery.

  3. Designing Drug Substance Processes For Fill-Finish Compatibility 2/4/2026

    Integrated KBI and Argonaut solutions streamline drug substance to fill-finish transitions, resolving quality challenges, reducing delays, and accelerating timelines through coordinated processes and practical strategies.

  4. The Value Of Engaging A Single CDMO For Comprehensive Biologics Services 2/4/2026

    By forging strategic partnerships with comprehensive CDMOs, see how emerging biopharma firms can navigate through early-phase development and ensure a smooth transition to clinical advancement.

  5. Protein Manufacturing Utilizing A Titerless Baculovirus Platform 2/4/2026

    Explore how an innovative titerless baculovirus platform accelerates protein manufacturing with enhanced scalability, reproducibility, and long-term virus stability for cutting-edge biologics production.

  6. Optimized Transient Production: Faster Preclinical Studies With Enhanced QC 2/4/2026

    Accelerate your path from discovery to clinic by leveraging high-quality plasmid DNA, optimized expression systems, and early developability assessments to streamline transient protein production.

  7. Development Of A Non-Standard Protein Therapeutic 2/4/2026

    Discover how a tailored development approach transformed a complex therapeutic protein into a candidate ready for early-stage clinical trials.

  8. The Power Of People: How A Stable, Experienced Team Drives CDMO Success 2/3/2026

    This message highlights a CDMO site’s commitment to quality, safety, excellence, experienced staff, stable workforce, and seamless clinical‑to‑commercial transfer to support client success.

  9. Engineering Reliability In Cell Therapy Manufacturing 2/3/2026

    A cell therapy manufacturing model built on precision planning, digital execution, lifecycle‑ready CMC systems, and transparent collaboration to achieve high reliability and reduce variability across programs.

  10. The Gateway Delivery To The Brain 1/30/2026

    Nose‑to‑brain delivery enables targeted neurological treatment by using direct neural pathways to boost precision and limit systemic exposure, with new formulations and devices driving rapid progress.